ESC Premium Access

New aspects on PCI

Event: ESC CONGRESS 2016
Topic: PCI: long-term outcome
Session type: Moderated Posters
Date: 29 August 2016
Time: 15:35 - 16:25

Congress Session

6 presentations in this session

Prognostic significance of incomplete revascularization and bystander coronary anatomy following percutaneous coronary intervention: an observational study of 6,755 patients with multivessel disease

Speaker: Doctor C. Ilsley (Harefield, GB)

Outcomes of a novel abluminal bioabsorbable versus durable polymer-coated everolimus-eluting stent in complex patients and coronary artery disease

Speaker: Doctor E. Pllaha (Msida, MT)

Comparison of long-term and short-term mortality after primary percutaneous coronary intervention for STEMI versus those with unstable angina/NSTEMI and stable angina

Speaker: Associate Professor D. Kim (Seoul, KR)

Long term clinical results of percutaneous coronary intervention for chronic total occlusions: Latest report from Retrograde Summit Registry

Speaker: Doctor K. Wagatsuma (Tsukuba, JP)

Application of the DAPT score to the results of the OPTIDUAL trial : is it a useful tool to identify the best candidates for extended DAPT after DES ?

Speaker: Professor G. Helft (Paris, FR)

Long-term clinical outcomes after the treatment with two-stent techniques using second generation drug-eluting stents for coronary bifurcation lesions

Speaker: Doctor M. Ohya (Kurashiki, JP)

6 speakers from this session

Doctor Charles Ilsley

Royal Brompton and Harefield NHS Foundation Trust, Harefield (United Kingdom of Great Britain & Northern Ireland)
0 follower

Doctor Elton Pllaha

Mater Dei Hospital, Msida (Malta)
0 follower

Associate Professor Dongbin Kim

Catholic University Medical College, Seoul (Korea (Republic of))
0 follower

Doctor Kenji Wagatsuma

Tsukuba Memorial Hospital, Tsukuba (Japan)
0 follower

Professor Gerard Helft

Institut de Cardiologie, Paris (France)
0 follower

Doctor Masanobu Ohya

Kurashiki Central Hospital, Cardiology Department, Kurashiki (Japan)
0 follower

This platform is supported by

logo Novo Nordisk